MedPath

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:0

Trial Phases

3 Phases

Phase 2:2
Phase 3:1
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (40.0%)
Phase 4
2 (40.0%)
Phase 3
1 (20.0%)

Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Phase 3
Conditions
Chemotherapy-induced Peripheral Neuropathy
Colorectal Cancer
Interventions
Drug: Mimetic granules of Yiqi-Wenjing prescriptions
Drug: Huangqi-Guizhi-Wuwu granules
Drug: Danggui-Sini granules
First Posted Date
2020-12-30
Last Posted Date
2020-12-30
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
360
Registration Number
NCT04690283

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Phase 2
Conditions
Peripheral T-cell Lymphomas
Interventions
Drug: GDP
Biological: Endostar
First Posted Date
2015-08-11
Last Posted Date
2015-08-11
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02520219
Locations
🇨🇳

Jiangsu province tumor hospital, Nanjing City, Jiangsu, China

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Phase 4
Conditions
Non-small Cell Lung Cancer
Interventions
Biological: Endostar
Drug: Changchun marina
Drug: parapl
First Posted Date
2015-07-31
Last Posted Date
2015-08-04
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
400
Registration Number
NCT02513355
Locations
🇨🇳

Jiangsu Taizhou People's Hospital, Nanjing City, Jiangsu, China

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Phase 4
Conditions
Advanced Lung Squamous Carcinoma
Interventions
Biological: Endostar
First Posted Date
2015-07-31
Last Posted Date
2015-07-31
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
400
Registration Number
NCT02513342
Locations
🇨🇳

Jinling Hospital, Nanjing, Jiangsu, China

🇨🇳

The first affiliated hospital of soochow university, Soochow, Jiangsu, China

Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Phase 2
Conditions
Colon Cancer
Interventions
Drug: mFOLFOX6
Drug: XELOX
Drug: Placebo ChangTai Keli
First Posted Date
2015-07-28
Last Posted Date
2015-08-03
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
360
Registration Number
NCT02510118
Locations
🇨🇳

Jiege Huo, Nanjing, Jiangsu, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.